• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Hepatic extraction of taurocholate and indocyanine green in patients with liver disease (author's transl)].

作者信息

Paumgartner G, Vasella D L, Herz R, Reichen J, Preisig R

出版信息

Z Gastroenterol. 1979 Nov;17(11):753-61.

PMID:524951
Abstract

Bile acids are increasingly used as test substances for the estimation of liver function and it has been postulated that radioactive labeled bile acids have advantages over indocyanine green (ICG) for measurement of hepatic blood flow. Therefore, the hepatic extractions of 14C-taurocholate and ICG were compared in 23 patients with liver disease and correlated with various parameters of hepatic function. The hepatic extractions of 14C-taurocholate (mean: 42 +/- SD 17%) and ICG (mean: 35 +/- SD 18%) were similar. The correlations with galactose elimination capacity and BSP plasma disappearance were closer for ICG than for 14C-taurocholate extraction. Hepatic blood flow measured with 14C-taurocholate (mean: 1.45 +/- SD 0.51 l/min) correlated well (r = 0.81) with the respective values obtained with ICG (mean: 1.17 +/- SD 0.49 l/min), but was about 22% larger. This study does not provide evidence that 14C-taurocholate is superior to ICG as an intravenous test substance for measurement of hepatic function or blood flow.

摘要

相似文献

1
[Hepatic extraction of taurocholate and indocyanine green in patients with liver disease (author's transl)].
Z Gastroenterol. 1979 Nov;17(11):753-61.
2
Extraction of 125I-albumin microaggregates from portal blood. An index of functional portal blood supply in cirrhotics.从门静脉血中提取125I-白蛋白微聚体。肝硬化患者门静脉功能性血供指标。
Gastroenterology. 1976 Jan;70(1):74-81.
3
[Prognostic value of hepatic clearance of indocyanine green in patients with liver cirrhosis and hemorrhage of esophageal varices].
Med Clin (Barc). 1992 Feb 29;98(8):290-4.
4
Relation of biliary bile acid output to hepatic adenosine triphosphate level and biliary indocyanine green excretion in humans.人体胆汁中胆汁酸分泌量与肝脏三磷酸腺苷水平及胆汁中吲哚菁绿排泄的关系
World J Surg. 2002 Apr;26(4):457-61. doi: 10.1007/s00268-001-0249-3. Epub 2002 Feb 4.
5
Effect of liver blood flow and function on hepatic indocyanine green clearance measured directly in a cirrhotic animal model.肝血流和功能对肝硬化动物模型中直接测量的肝脏吲哚菁绿清除率的影响。
Br J Surg. 2000 May;87(5):568-74. doi: 10.1046/j.1365-2168.2000.01399.x.
6
Hepatic parenchymal cell volume and the indocyanine green tolerance test.肝实质细胞体积与吲哚菁绿耐受试验
J Surg Res. 2000 Aug;92(2):222-7. doi: 10.1006/jsre.2000.5893.
7
Sorbitol as a test substance for measurement of liver plasma flow in humans.
Hepatology. 1998 Jul;28(1):50-6. doi: 10.1002/hep.510280109.
8
Indocyanine green clearance test and model for end-stage liver disease score of patients with liver cirrhosis.肝硬化患者的吲哚菁绿清除试验及终末期肝病模型评分
Hepatobiliary Pancreat Dis Int. 2009 Feb;8(1):46-9.
9
[Aspects of bile acid metabolism in liver diseases(author's transl)].[肝脏疾病中胆汁酸代谢的各个方面(作者译)]
Acta Med Austriaca Suppl. 1975;4:1-38.
10
Hepatic plasma flow estimated according to Fick's principle in patients with hepatic encephalopathy: evaluation of indocyanine green and D-sorbitol as test substances.根据菲克原理估算肝性脑病患者的肝血浆流量:评价吲哚菁绿和D-山梨醇作为测试物质的情况。
Hepatology. 1998 Mar;27(3):666-73. doi: 10.1002/hep.510270305.

引用本文的文献

1
Sodium-dependent bile salt transporters of the SLC10A transporter family: more than solute transporters.SLC10 家族钠离子依赖型胆盐转运体:不仅仅是溶质转运体。
Pflugers Arch. 2014 Jan;466(1):77-89. doi: 10.1007/s00424-013-1367-0. Epub 2013 Oct 3.
2
Effect of cimetidine on the hepatic extraction of indocyanine green, the portal pressure and the systemic circulation in patients with cirrhosis of the liver.西咪替丁对肝硬化患者肝脏摄取吲哚菁绿、门静脉压力及体循环的影响。
Klin Wochenschr. 1984 Aug 16;62(16):759-64. doi: 10.1007/BF01721773.
3
Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
Eur J Clin Pharmacol. 1986;30(4):407-16. doi: 10.1007/BF00607952.